Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Shareholding

10 Jun 2009 15:39

RNS Number : 6964T
ReGen Therapeutics PLC
10 June 2009
 



10th June 2009

REGEN THERAPEUTICS PLC 

("ReGen" or the "Company"; Ticker: (RGT))

TR-1(i): NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii):

 

ReGen Therapeutics Plc

 

2. Reason for the notification:

 

An acquisition or disposal of voting rights 

 

3. Full name of person(s) subject to the notification obligation (iii):

 

Barclays PLC

 

4. Full name of shareholder(s) (if difference from 3):

 

Barclays Stockbrokers Ltd

 

5. Date of the transaction and date on which the threshold is crossed or reached (v):

 

8th June 2009

 

6. Date on which issuer notified:

 

10th June 2009

 

7. Threshold(s) that is/are crossed or reached:

 

13% to 12%

 

8. Notified details 

A: Voting rights attached to shares

Class/type of share if possible using the ISIN Code GB00B28XMY25

Situation Previous to the triggering transaction (vi) -

Number of Shares 3,401,978

Number of Voting Rights (viii) 3,401,978

Resulting situation after the triggering transaction (viii) -

Number of Shares 3,312,133

Number of Voting Rights - Direct (x) N/A

Number of Voting Rights - Indirect (xi) 3,312,133

% of voting rights - Direct N/A

% of voting rights - Indirect 12.97

B: Financial Instruments

Resulting situation after the triggering transaction (xii)

Type of financial instrument N/A

Expiration date (xiii) N/A

Exercise/Conversion Period/Date (xiv) N/A

Number of voting rights that may be acquired if the 

instrument is exercised/converted N/A

% of voting rights N/A

Total (A+B)

Number of voting rights 3,312,133

% of voting rights 12.97

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if 

applicable (xv): Barclays Stockbrokers Ltd

Proxy Voting:

 

10. Name of the proxy holder: N/A

 

11. Number of voting rights proxy holder will cease to hold: N/A

 

12. Date on which proxy holder will cease to hold voting rights: N/A

 

13. Additional information: N/A

 

14. Contact name: Geoff Smith

 

15. Contact telephone number: 0207 116 2913

For further information:

For further information, please contact: Percy Lomax ReGen Therapeutics Plc Tel: 020 7153 4920 Roland Cornish/Felicity Geidt Beaumont Cornish Limited Tel: 020 7628 3396 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLFMMITMMJBBFL
Date   Source Headline
17th Sep 20207:00 amRNSClinical Study with Nasally Administered Foralumab
16th Sep 20209:05 amRNSSecond Price Monitoring Extn
16th Sep 20209:00 amRNSPrice Monitoring Extension
16th Sep 20207:00 amRNSDemerger of StemPrintER and Distribution in Specie
7th Sep 202011:05 amRNSSecond Price Monitoring Extn
7th Sep 202011:00 amRNSPrice Monitoring Extension
2nd Sep 20204:41 pmRNSSecond Price Monitoring Extn
2nd Sep 20204:35 pmRNSPrice Monitoring Extension
2nd Sep 20202:06 pmRNSSecond Price Monitoring Extn
2nd Sep 20202:00 pmRNSPrice Monitoring Extension
28th Aug 202012:04 pmRNSHolding(s) in Company
28th Aug 202010:30 amRNSADS Registration Statement Filing Clarification
27th Aug 20204:00 pmRNSExercise of Warrants and Issue of Equity
27th Aug 20207:00 amRNSTiziana CEO Interview
26th Aug 20207:00 amRNSGrant of Options - Director Dealings
24th Aug 20207:00 amRNSPatent Granted for Anti-IL-6/IL-6
21st Aug 20207:00 amRNSPatent Granted for Milciclib
20th Aug 20207:00 amRNSUpdate - Scientific Advisory Board
18th Aug 20209:05 amRNSSecond Price Monitoring Extn
18th Aug 20209:00 amRNSPrice Monitoring Extension
18th Aug 20207:00 amRNSPatent Granted for Foralumab
11th Aug 20208:49 amRNSBTIG's Virtual Biotechnology Conference
10th Aug 20207:00 amRNSHolding(s) in Company
5th Aug 20204:00 pmRNSClosing of $57.25 Million Offering
4th Aug 20207:00 amRNSExpedited Clinical Development Plan
3rd Aug 20207:00 amRNSIssue of Equity
31st Jul 20205:00 pmRNSTotal Voting Rights
31st Jul 20204:41 pmRNSSecond Price Monitoring Extn
31st Jul 20204:35 pmRNSPrice Monitoring Extension
31st Jul 20207:00 amRNSSubmission of a Patent Application for Foralumab
30th Jul 20204:30 pmRNSProposed Admission to the Official List
30th Jul 202011:53 amRNSUpdate on Timings and Corporate Actions
30th Jul 20207:00 amRNSInvestor Webinar to Provide Corporate Updates
29th Jul 20202:05 pmRNSSecond Price Monitoring Extn
29th Jul 20202:00 pmRNSPrice Monitoring Extension
24th Jul 20207:00 amRNSExercise of Warrants and Issue of Equity
20th Jul 20202:51 pmRNSDirector Appointment
20th Jul 20209:05 amRNSSecond Price Monitoring Extn
20th Jul 20209:00 amRNSPrice Monitoring Extension
16th Jul 202011:39 amRNSResult of AGM
16th Jul 20207:00 amRNSSubmission of Patent Application
15th Jul 20204:29 pmRNSChange to ADS Ratio - Updated
15th Jul 20201:00 pmRNSChange to ADS Ratio
14th Jul 20209:06 amRNSSecond Price Monitoring Extn
14th Jul 20209:00 amRNSPrice Monitoring Extension
13th Jul 20204:41 pmRNSSecond Price Monitoring Extn
13th Jul 20204:36 pmRNSPrice Monitoring Extension
10th Jul 20206:01 pmRNSInterview to Air on Bloomberg International
1st Jul 20207:00 amRNSTotal Voting Rights and StemPrintER Update
29th Jun 202011:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.